Stock analysts at SunTrust Banks, Inc. initiated coverage on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a note issued to investors on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $115.00 price target on the biotechnology company’s stock. SunTrust Banks, Inc.’s target price indicates a potential upside of 50.05% from the company’s previous close. SunTrust Banks also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.44) EPS, FY2017 earnings at ($1.69) EPS, Q1 2018 earnings at ($0.51) EPS, Q2 2018 earnings at ($0.64) EPS, Q3 2018 earnings at ($0.72) EPS, Q4 2018 earnings at ($0.80) EPS, FY2018 earnings at ($2.68) EPS, FY2019 earnings at ($3.65) EPS, FY2020 earnings at ($4.45) EPS and FY2021 earnings at ($4.65) EPS.

ANAB has been the topic of several other research reports. Stifel Nicolaus reissued a “buy” rating and issued a $35.00 price objective on shares of AnaptysBio in a research note on Tuesday, September 12th. Royal Bank Of Canada increased their price objective on AnaptysBio from $40.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 10th. Zacks Investment Research raised AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a research note on Wednesday, September 13th. Robert W. Baird set a $69.00 price objective on AnaptysBio and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Finally, Jefferies Group LLC assumed coverage on AnaptysBio in a research note on Thursday, November 9th. They issued a “buy” rating and a $101.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $84.78.

AnaptysBio (NASDAQ:ANAB) traded up $1.78 on Wednesday, hitting $76.64. The stock had a trading volume of 340,201 shares, compared to its average volume of 293,749. AnaptysBio has a 1 year low of $15.17 and a 1 year high of $79.18. The company has a current ratio of 10.77, a quick ratio of 10.77 and a debt-to-equity ratio of 0.09.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. equities research analysts predict that AnaptysBio will post -1.72 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/19/anaptysbio-inc-anab-now-covered-by-analysts-at-suntrust-banks-inc.html.

In other AnaptysBio news, major shareholder Holdings A/S Novo sold 356,300 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the sale, the insider now owns 1,936,604 shares in the company, valued at $40,862,344.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC lifted its holdings in AnaptysBio by 3.2% during the third quarter. Perceptive Advisors LLC now owns 982,269 shares of the biotechnology company’s stock worth $34,330,000 after buying an additional 30,000 shares during the period. Citadel Advisors LLC purchased a new stake in AnaptysBio during the third quarter worth $20,406,000. Artal Group S.A. lifted its holdings in AnaptysBio by 459.4% during the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares during the period. Vanguard Group Inc. lifted its holdings in AnaptysBio by 22.6% during the second quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock worth $4,931,000 after buying an additional 37,932 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in AnaptysBio by 210.2% during the third quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock worth $6,363,000 after buying an additional 124,219 shares during the period. Institutional investors own 73.05% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.